Lerkanidipin Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L-type calcium channels located on vascular smooth‑muscle cells. By blocking calcium entry, it prevents muscle contraction, leading to vasodilation of arterial vessels. The resulting reduction in peripheral vascular resistance lowers systolic and diastolic blood pressure without significantly affecting heart rate or cardiac contractility.

The appropriate dose of Lerkanidipin Actavis is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. The prescriber will select the initial dose and may adjust it during follow‑up visits to achieve optimal blood pressure control.

Safety data for lercanidipine in pregnancy and lactation are limited. Because potential risks cannot be ruled out, the drug is generally avoided unless the expected benefit justifies the potential danger to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lerkanidipin Actavis. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and assists with any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine calcium‑channel blocker class and lower blood pressure by causing arterial vasodilation. Lercanidipine has a longer half‑life and may provide smoother 24‑hour blood pressure control, while amlodipine is more widely used and has a well‑established safety profile. Choice of therapy depends on individual patient response, tolerability, and physician preference.

Lerkanidipin Actavis tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

The medication is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a full glass of water and not crushed, chewed, or broken, unless the prescriber provides specific instructions for dose adjustment.

Serious adverse events, although rare, include severe hypotension, angioedema, myocardial infarction, and significant hepatic dysfunction. Patients should be instructed to seek immediate medical attention if they experience sudden swelling of the face or throat, chest pain, fainting, or signs of liver injury such as jaundice or dark urine.

Lerkanidipin Actavis is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, in those with severe hypotension or cardiogenic shock, and in individuals with unstable angina. Caution is also advised for patients with severe hepatic impairment, as drug clearance may be reduced.